Sonova (OTCMKTS:SONVY) Upgraded by BNP Paribas Exane to Strong-Buy Rating

BNP Paribas Exane upgraded shares of Sonova (OTCMKTS:SONVY) from a strong sell rating to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

A number of other analysts have also commented on the company. Royal Bank Of Canada raised Sonova to a “moderate buy” rating in a research note on Tuesday, November 18th. Zacks Research upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Sonova Stock Performance

Shares of SONVY stock opened at $51.10 on Tuesday. Sonova has a twelve month low of $47.55 and a twelve month high of $68.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.91 and a current ratio of 1.24. The stock’s fifty day simple moving average is $52.83 and its 200 day simple moving average is $53.77.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.